GLP-1 receptor agonist therapy was associated with lower all-cause mortality and fewer heart failure events compared with bariatric surgery in obese patients with hypertrophic cardiomyopathy.
Does GLP-1 RA therapy reduce all-cause mortality and HF events in obese patients with hypertrophic cardiomyopathy compared to bariatric surgery?
In obese patients with hypertrophic cardiomyopathy, GLP-1 receptor agonists are associated with lower mortality and fewer heart failure events compared to bariatric surgery.
Absolute Event Rate: 0% vs 0%
In obese patients with HCM, GLP-1 RA therapy was associated with lower all-cause mortality and fewer HF events compared with BS. Future studies are warranted to confirm our findings.
Mahmoud et al. (Thu,) reported a other. GLP-1 receptor agonist therapy was associated with lower all-cause mortality and fewer heart failure events compared with bariatric surgery in obese patients with hypertrophic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: